GAOMA Therapeutics is a biotech company specialized in the development of lipids derivatives as innovative therapeutic molecules. Lipids are a class of compounds that has been largely under-exploited, whereas it plays a key role in many medical conditions. GAOMA has the ambition to tap into the therapeutic potential of lipids. The company’s first drug candidate, GAO-3-02, is a novel patented active ingredient. It aims to address epilepsy and cognitive disorders, by targeting neuroinflammation and brain plasticity. In various preclinical experiments, GAO-3-02 has thus demonstrated its ability to limit seizures, protect and restore cognitive functions, on the long term, and with a good tolerance. With 50 to 70 million people affected in the world, epilepsy is one of the most common severe neurological conditions. The disease triggers seizures in patients, a phenomenon well known to the general public, but also various other disorders, such as cognitive impairment. Existing anti-epileptic drugs have relatively similar mechanisms of action, with the direct objective to disable neuronal activity. These drugs unfortunately leave a high unmet medical need: they are symptomatic treatments addressing seizures only, with a limited efficacy (one third of patients is drug resistant), and with poor tolerance (side effects among a majority of patients).